Pluristem Therapeutics Inc.
(NasdaqCM: PSTI) (DAX: PJT) today announced that it appointed Dr. Aristidis Veves to the company’s Scientific Advisory Board.
Dr. Veves brings more than 30 years of experience in the field of diabetic neuropathy and vascular disease. An expert in diabetic foot problems and vascular reactivity, Dr. Veves is the research director of the Joslin-Beth Israel Deaconess Foot Center and of the Microcirculation Lab, as well as an associate professor at Harvard Medical School. Dr. Veves’ research focuses on techniques that will identify patients at risk of developing diabetic foot problems at the early stages and therapeutic strategies that will prevent or slow the progression of this condition.
“Dr. Veves is a highly regarded thought leader in diabetic neuropathy and vascular disease, common in patients with Critical Limb Ischemia (CLI),” said Dr. Edwin Horwitz, Chairman of Pluristem’s Scientific Advisory Board. “His appointment to our advisory board will bring invaluable expertise and perspective in diabetic neurological conditions and wound care that will be necessary as Pluristem progresses through clinical studies with its placenta-derived cell therapies.”
Dr. Veves added, “Clinical results suggest that Pluristem’s product for peripheral artery disease, PLX-PAD, is potentially a safe, well tolerated and effective treatment for patients with diabetic foot and wound healing problems. I look forward to contributing to PLX-PAD’s clinical advancement as well as helping apply Pluristem’s technology to other neurological and wound care indications.”
Zami Aberman, Chairman and CEO of Pluristem, added: “We at Pluristem are extremely pleased that a researcher of Dr. Veves’ caliber is joining our Scientific Advisory Board and we believe his contributions will be valuable as we enter the neurologic and wound care markets with our PLX cells.”
Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. In April 2010, Pluristem reported interim top-line results from Phase I clinical trials of PLX-PAD that demonstrated the cell therapy is potentially safe, well tolerated and effective in patients with critical limb ischemia (CLI).